Tag: ChAdOx1
Efficacy of the AstraZeneca coronavirus vaccine against the B.1.351 South African Variant
Study conclusions: A two-dose regimen of the ChAdOx1 nCoV-19 [AstraZeneca] vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 [South Africa ] variant. More...
Oxford University: “vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK”
“Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B.1.1.7”
The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it remains effective against one of the new variants of the disease. More...